CIBC Private Wealth Group
CNCR

CIBC Private Wealth Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

CIBC Private Wealth Group’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-505
Closed -$12K – 1095
2018
Q2 		$12K Hold
505
– – ﹤0.01% 1514
2018
Q1 		$15K Buy
505
+5
+1% +$142 ﹤0.01% 1440
2017
Q4 		$12K Buy
+500
New +$12.6K ﹤0.01% 1501

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return

CIBC Private Wealth Group's CNCR Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2018, closing a stake of 505 shares — an estimated $12K sold.

CIBC Private Wealth Group first reported a position in CNCR in Q4 2017 and held it in 3 quarters. The position peaked at $15K in Q1 2018. 23 funds tracked by Wall St. Rank hold CNCR as of Q3 2018.

  • CIBC Private Wealth Group reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 505 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2018, an estimated $12K.
  • CIBC Private Wealth Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2017 and held it in 3 quarters.
  • CIBC Private Wealth Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $15K in Q1 2018.
  • 23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.